Proteostasis Therapeutics Priced, Nasdaq: PTI

Developing a protein modulator to treat cystic fibrosis.

Industry: Health Care

Latest Trade: $1.99 0.00 (0.0%)

First Day Return: -17.0%

Return from IPO: -75.1%

Industry: Health Care

We are an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. Our initial therapeutic focus is on cystic fibrosis, or CF, which is caused by defects in the cystic fibrosis transmembrane conductance regulator, or CFTR, protein and insufficient CFTR protein function. CF is an orphan disease that affects an estimated 70,000 to 100,000 patients worldwide, with the vast majority of affected individuals in the United States, Canada, Europe and Australia. CF is the most common fatal inherited disease in Caucasians, and there is presently no cure.
more less
IPO News for Proteostasis Therapeutics
more
IPO Data
IPO File Date 12/23/2015
Offer Price $8.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.3
Deal Size ($mm) $50
IPO Data
IPO Date 02/10/2016
Offer Price $8.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.3
Deal Size ($mm) $50
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2006
Employees 42
Website www.proteostasis.com